7CYP

Complex of SARS-CoV-2 spike trimer with its neutralizing antibody HB27

Summary for 7CYP

• Entry DOI: 10.2210/pdb7cyp/pdb
• Related: 7CYH
• EMDB information: 30500 30503
• Descriptor: SARS-CoV-2 Spike glycoprotein, Light chain of HB27, Heavy chain of HB27, ... (5 entities in total)
• Functional Keywords: sars-cov-2 spike, neutralizing antibody, complex, viral protein
• Biological source: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV); More
• Total number of polymer chains: 9
• Total formula weight: 488893.47

Authors

Wang, X.,Zhu, L. (deposition date: 2020-09-04, release date: 2021-06-09, Last modification date: 2025-07-02)

Primary citation

Zhu, L.,Deng, Y.Q.,Zhang, R.R.,Cui, Z.,Sun, C.Y.,Fan, C.F.,Xing, X.,Huang, W.,Chen, Q.,Zhang, N.N.,Ye, Q.,Cao, T.S.,Wang, N.,Wang, L.,Cao, L.,Wang, H.,Kong, D.,Ma, J.,Luo, C.,Zhang, Y.,Nie, J.,Sun, Y.,Lv, Z.,Shaw, N.,Li, Q.,Li, X.F.,Hu, J.,Xie, L.,Rao, Z.,Wang, Y.,Wang, X.,Qin, C.F.
Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2.
Natl Sci Rev, 8:nwaa297-nwaa297, 2021

PubMed Abstract: Receptor recognition and subsequent membrane fusion are essential for the establishment of successful infection by SARS-CoV-2. Halting these steps can cure COVID-19. Here we have identified and characterized a potent human monoclonal antibody, HB27, that blocks SARS-CoV-2 attachment to its cellular receptor at sub-nM concentrations. Remarkably, HB27 can also prevent SARS-CoV-2 membrane fusion. Consequently, a single dose of HB27 conferred effective protection against SARS-CoV-2 in two established mouse models. Rhesus macaques showed no obvious adverse events when administrated with 10 times the effective dose of HB27. Cryo-EM studies on complex of SARS-CoV-2 trimeric S with HB27 Fab reveal that three Fab fragments work synergistically to occlude SARS-CoV-2 from binding to the ACE2 receptor. Binding of the antibody also restrains any further conformational changes of the receptor binding domain, possibly interfering with progression from the prefusion to the postfusion stage. These results suggest that HB27 is a promising candidate for immuno-therapies against COVID-19.

PubMed: 34676096
DOI: 10.1093/nsr/nwaa297

Experimental method

ELECTRON MICROSCOPY (3.5 Å)